Alabama Medical Cannabis Sales Begin After Years of Delays

Sales Commence Five Years After Legislative Authorization

Alabama's medical cannabis program opened for retail sales on June 4, 2026, ending a five-year implementation period that began with the passage of SB 46 in May 2021. The Alabama Medical Cannabis Commission (AMCC) issued final dispensary licenses in late 2025, clearing the path for patient access. Qualifying conditions include cancer, chronic pain, epilepsy, PTSD, and terminal illnesses.

The delay between authorization and implementation reflects the operational complexity of building a regulated supply chain from scratch. Alabama required cultivators, processors, testing labs, and dispensaries to obtain separate licenses and meet facility standards before any product could reach patients. The AMCC conducted multiple rounds of scoring and appeals before finalizing the license roster.

Alabama becomes the 38th state to operationalize a medical cannabis program. The state doesn't permit adult-use sales, and the medical program caps THC content at 9% for flower and prohibits smokable products entirely. Patients must obtain a recommendation from a qualified physician and register with the AMCC to receive a medical cannabis card.

Initial Dispensary Count and Geographic Distribution

The AMCC awarded licenses to four vertically integrated operators, each authorized to open multiple dispensary locations across the state's designated regions. The commission divided Alabama into seven zones to ensure geographic access, with at least one dispensary required in each zone. Twelve active dispensary locations opened in the initial phase, concentrated in Birmingham, Mobile, Huntsville, and Montgomery.

Rural patients face longer travel distances. The AMCC hasn't authorized home delivery, requiring all transactions to occur at brick-and-mortar dispensaries. The commission plans to review delivery options in 2027, according to public meeting minutes from April 2026.

The vertically integrated model limits competition but accelerates supply-chain coordination. Each licensee operates cultivation, processing, and retail under a single corporate structure, reducing the risk of supply shortages during the ramp-up phase. The AMCC has signaled it may open additional licenses in 2028 if patient demand exceeds current capacity.

Product Availability and Pricing Dynamics

Dispensaries launched with a limited menu of tinctures, capsules, gels, and vaporizable oils, with no flower products available due to Alabama's smokable-cannabis ban. Patients reported first-day prices ranging from $45 to $70 per gram of THC-equivalent product, according to social media posts reviewed by CannIntel. The AMCC doesn't regulate retail pricing. Operators set margins based on production costs and competitive positioning.

Alabama's THC cap creates a pricing ceiling effect. Operators can't differentiate on potency above 9%, shifting competition to brand, terpene profiles, and patient education. The cap also limits the addressable patient population; individuals seeking higher-potency products for severe chronic pain may continue to source from neighboring states with reciprocity agreements or from unregulated channels.

Alabama collected $2.3 million in application and licensing fees during the buildout phase, according to AMCC financial disclosures. The state imposes a 9% excise tax on gross receipts at the dispensary level, with revenue earmarked for the state general fund and the University of Alabama at Birmingham's medical cannabis research program. First-month sales data won't be public until the AMCC's August 2026 board meeting.

What Comes Next for Alabama's Program

The AMCC will monitor patient enrollment and product availability through quarterly reporting requirements imposed on all licensees. The commission has authority to expand the list of qualifying conditions and adjust THC limits through rulemaking, though no proposals are currently under review. Advocates continue to push for the inclusion of smokable flower and higher THC caps, citing patient preference data from other medical states.

Alabama doesn't participate in interstate cannabis commerce, and federal Schedule I classification prohibits banks from processing cannabis transactions without state-chartered workarounds. Most Alabama dispensaries operate on a cash-only basis, though some accept debit cards through point-of-sale systems that code transactions as ATM withdrawals.

For full background on this story, see the CannIntel topic hub on Alabama's medical cannabis program. Next regulatory milestone: the AMCC's August 2026 meeting, where commissioners will review first-quarter sales data and consider amendments to the qualifying-conditions list.